Yet the view persists that adolescents are somehow immune to the debilitating clinical depression that afflicts many adults. And such carefree-days-of-youth thinking on the part of some parents and caregivers can yield tragic results.
Teen suicides, which had been on a downward trajectory for the previous two decades, showed an 18 percent rise in 2004 over the previous year, according to a recent report by Journal of the American Medical Association. Although the rate dipped slightly in 2005, the most recent year charted, the number remains well above predicted levels.
As for depression, the World Health Organization reports that one in 33 children and, among them, one in eight teens, is clinically depressed. The organization predicts those numbers could double by 2020.
READ MORE @ SACRAMENTO BEE
Tuesday, October 14, 2008
Monday, October 13, 2008
Antidepressants Could Improve Symptoms of Irritable Bowel Syndrome: Presented at ACG
Antidepressants are an effective treatment for patients with irritable bowel syndrome (IBS), according to results presented here at the American College of Gastroenterology (ACG) 73rd Annual Scientific Meeting.
Alexander Ford, MD, McMaster University Medical Centre, Hamilton, Ontario, reported the results of a systematic review in a poster session here on October 5.
"I think the most exciting finding [of our study] is that this hasn't been shown before. It's probably the first time that a systematic review and meta-analysis has shown that antidepressants are a benefit in treating irritable bowel syndrome," said Dr. Ford.
"Previous meta-analyses have not demonstrated such an effect for a number of reasons. Obviously, there's more data now but also [researchers] haven't quite looked at all of the eligible studies for various reasons. I think one of [the studies] should have been able to demonstrate this benefit 3 or 4 years ago, but just didn't manage to."
READ MORE @ DOCTOR'S GUIDE
Alexander Ford, MD, McMaster University Medical Centre, Hamilton, Ontario, reported the results of a systematic review in a poster session here on October 5.
"I think the most exciting finding [of our study] is that this hasn't been shown before. It's probably the first time that a systematic review and meta-analysis has shown that antidepressants are a benefit in treating irritable bowel syndrome," said Dr. Ford.
"Previous meta-analyses have not demonstrated such an effect for a number of reasons. Obviously, there's more data now but also [researchers] haven't quite looked at all of the eligible studies for various reasons. I think one of [the studies] should have been able to demonstrate this benefit 3 or 4 years ago, but just didn't manage to."
READ MORE @ DOCTOR'S GUIDE
Sunday, October 12, 2008
The long, wild ride of bipolar disorder - A severe childhood mood disorder often lasts into young adulthood
Children who grow up with the psychiatric ailment known as bipolar disorder rarely grow out of it. Almost half of youngsters who suffered from bipolar’s severe, rapid-fire mood swings at around age 11 displayed much of the same emotional volatility at ages 18 to 20, even if the condition had improved for a while during their teens, according to the first long-term study of children diagnosed with the disorder.
Bipolar disorder took off with a vengeance in these kids. Initial episodes, often periods of frequent, dramatic mood swings, lasted for up to three years. Second episodes lasted for slightly more than one year, while third episodes continued for roughly 10 months.
During these periods, youngsters can veer back and forth several times a day between a manic sense of euphoria and a serious, even suicidal depression, say psychiatrist Barbara Geller of Washington University in St. Louis and her colleagues. Manic euphoria typically includes grandiose delusions or hallucinations.
READ MORE @ SCIENCE NEWS
Bipolar disorder took off with a vengeance in these kids. Initial episodes, often periods of frequent, dramatic mood swings, lasted for up to three years. Second episodes lasted for slightly more than one year, while third episodes continued for roughly 10 months.
During these periods, youngsters can veer back and forth several times a day between a manic sense of euphoria and a serious, even suicidal depression, say psychiatrist Barbara Geller of Washington University in St. Louis and her colleagues. Manic euphoria typically includes grandiose delusions or hallucinations.
READ MORE @ SCIENCE NEWS
Friday, October 10, 2008
Millions with mental disorders in the developing world are deprived of necessary treatment and care
More than 75% of people suffering from mental disorders in the developing world receive no treatment or care. A new WHO programme launched today, on World Mental Health Day 2008 highlights the huge treatment gap for a number of mental, neurological and substance use disorders. Across Africa for example, nine out of ten people suffering from epilepsy go untreated, unable to access simple and inexpensive anticonvulsant drugs which cost less than US$5 a year per person.
WHO is now calling on governments, donors and mental health stakeholders to rapidly increase funding and basic mental health services to close this huge treatment gap. The programme, Mental health Gap Action Programme (mhGAP): Scaling up care for mental, neurological and substance use disorders asserts that with proper care, psychosocial assistance and medication, tens of millions could be treated for diseases such as depression, schizophrenia, and epilepsy and begin to lead healthy lives, even where resources are scarce.
“Governments across the world need to see mental health as a vital component of primary health care. We need to change policy and practice. Only then can we get the essential mental health services to the tens of millions in need”, said Dr Margaret Chan, Director-General of the World Health Organ.
READ MORE @ WORLD HEALTH ORGANIZATION
WHO is now calling on governments, donors and mental health stakeholders to rapidly increase funding and basic mental health services to close this huge treatment gap. The programme, Mental health Gap Action Programme (mhGAP): Scaling up care for mental, neurological and substance use disorders asserts that with proper care, psychosocial assistance and medication, tens of millions could be treated for diseases such as depression, schizophrenia, and epilepsy and begin to lead healthy lives, even where resources are scarce.
“Governments across the world need to see mental health as a vital component of primary health care. We need to change policy and practice. Only then can we get the essential mental health services to the tens of millions in need”, said Dr Margaret Chan, Director-General of the World Health Organ.
READ MORE @ WORLD HEALTH ORGANIZATION
Monday, October 6, 2008
Side-Effects of Antipsychotics
A new federally funded study will examine ways to control the metabolic side effects associated with the use of the newer atypical antipsychotic medications in children with schizophrenia or bipolar disorder.
The use of atypical antipsychotic medications to treat children and adolescents with schizophrenia or bipolar disorder is relatively common, but the side effects associated with them are troubling.
The recent NIMH-funded Treatment of Early Onset Schizophrenia Study (TEOSS) found that two atypical medications were associated with more metabolic side effects than an older generation antipsychotic.
The new grant will test ways in which the metabolic side effects, such as weight gain, insulin sensitivity and other factors that can lead to type 2 diabetes and heart disease, may be controlled or reduced.
READ MORE @ PSYCHCENTRAL
The use of atypical antipsychotic medications to treat children and adolescents with schizophrenia or bipolar disorder is relatively common, but the side effects associated with them are troubling.
The recent NIMH-funded Treatment of Early Onset Schizophrenia Study (TEOSS) found that two atypical medications were associated with more metabolic side effects than an older generation antipsychotic.
The new grant will test ways in which the metabolic side effects, such as weight gain, insulin sensitivity and other factors that can lead to type 2 diabetes and heart disease, may be controlled or reduced.
READ MORE @ PSYCHCENTRAL
Sunday, October 5, 2008
Bailout Provision Provides Equal Coverage for Mental and Physical Ailments
More than one-third of all Americans will soon receive better insurance coverage for mental health treatments because of a new law that, for the first time, requires equal coverage of mental and physical illnesses.
The requirement, included in the economic bailout bill that President Bush signed on Friday, is the result of 12 years of passionate advocacy by friends and relatives of people with mental illness and addiction disorders. They described the new law as a milestone in the quest for civil rights, an effort to end insurance discrimination and to reduce the stigma of mental illness.
Most employers and group health plans provide less coverage for mental health care than for the treatment of physical conditions like cancer, heart disease or broken bones. They will need to adjust their benefits to comply with the new law, which requires equivalence, or parity, in the coverage.
READ MORE @ NY TIMES
The requirement, included in the economic bailout bill that President Bush signed on Friday, is the result of 12 years of passionate advocacy by friends and relatives of people with mental illness and addiction disorders. They described the new law as a milestone in the quest for civil rights, an effort to end insurance discrimination and to reduce the stigma of mental illness.
Most employers and group health plans provide less coverage for mental health care than for the treatment of physical conditions like cancer, heart disease or broken bones. They will need to adjust their benefits to comply with the new law, which requires equivalence, or parity, in the coverage.
READ MORE @ NY TIMES
Saturday, October 4, 2008
Seeking Treatment for Mental Disorders Has Lasting Effect
Middle-age patients taking medication for anxiety or depression are less likely to have mental disorders a decade later, a population-based study showed.
Among 157 patients who had a mental disorder at age 43, those who took antidepressants, anxiolytics, or both were 70% less likely to have a disorder 10 years later (OR 0.3, 95% CI 0.1 to 1.0), Ian Colman, Ph.D., of the University of Alberta here, and colleagues reported in the October issue of the British Journal of Psychiatry.
"What this tells us is that, if people get treated initially, they are less likely to have a relapse in the future," Dr. Colman said.
Because only 24.2% of those taking medications at age 43 were still being treated at age 53, the researchers said, the lasting benefits of taking antidepressants and anxiolytics "may be because of a demonstrated willingness to seek help rather than long-term maintenance therapy."
They said the lasting benefit may be "explained by an initial willingness to be treated, potential successful initial treatment, and an increased likelihood that these patients would seek and accept help when encountering symptoms of depression and anxiety in the future."
READ MORE @ MEDPAGE TODAY
Among 157 patients who had a mental disorder at age 43, those who took antidepressants, anxiolytics, or both were 70% less likely to have a disorder 10 years later (OR 0.3, 95% CI 0.1 to 1.0), Ian Colman, Ph.D., of the University of Alberta here, and colleagues reported in the October issue of the British Journal of Psychiatry.
"What this tells us is that, if people get treated initially, they are less likely to have a relapse in the future," Dr. Colman said.
Because only 24.2% of those taking medications at age 43 were still being treated at age 53, the researchers said, the lasting benefits of taking antidepressants and anxiolytics "may be because of a demonstrated willingness to seek help rather than long-term maintenance therapy."
They said the lasting benefit may be "explained by an initial willingness to be treated, potential successful initial treatment, and an increased likelihood that these patients would seek and accept help when encountering symptoms of depression and anxiety in the future."
READ MORE @ MEDPAGE TODAY
Friday, October 3, 2008
Long-term psychotherapy is superior, study finds
Psychotherapy lasting for at least one year is more effective than shorter periods of therapy for people with complex mental disorders, such as personality and chronic disorders, according to a study published today in the Journal of the American Medical Assn. The success of dedicated psychotherapy may matter little, however, because fewer doctors are offering the service and fewer insurers are covering it.
In long-term psychodynamic psychotherapy, the therapist provides continued, close support for the patient while the pair work through problems and interventions. The JAMA study, from researchers in Germany, was an examination of 23 studies on the success of psychotherapy. It found that longer-term therapy (one year or longer) was superior to shorter-term methods in regard to overall outcome and personality functioning. On average, patients with complex mental conditions who were treated long-term were better off than 96% of the patients in the comparison groups.
READ MORE @ LOS ANGELES TIMES
In long-term psychodynamic psychotherapy, the therapist provides continued, close support for the patient while the pair work through problems and interventions. The JAMA study, from researchers in Germany, was an examination of 23 studies on the success of psychotherapy. It found that longer-term therapy (one year or longer) was superior to shorter-term methods in regard to overall outcome and personality functioning. On average, patients with complex mental conditions who were treated long-term were better off than 96% of the patients in the comparison groups.
READ MORE @ LOS ANGELES TIMES
Thursday, October 2, 2008
Depression linked to higher death rates from all causes among elderly with diabetes
2-year study looked at more than 10,000 Medicare beneficiaries with diabetes
In a large group of Medicare beneficiaries with diabetes, depression was associated with a higher death rate from all causes during a two-year study period. The findings are published in the October 2008 Journal of General Internal Medicine.
Lead author Dr. Wayne Katon, professor of psychiatry and behavioral sciences at the University of Washington (UW), noted that previous research indicates that depression and diabetes is a potentially lethal mix among young to middle-aged patients. Depression also puts patients at greater risk of complications from their diabetes. This more recent study suggests that depression is also a risk factor for mortality in older patients with diabetes. Most Medicare beneficiaries, like the ones in this study, are over age 65. The mean age of the participants was 75.6 years.
The study tracked 10,704 Medicare beneficiaries with diabetes who were enrolled in a disease management program in Florida. They were surveyed at the start of the study with a health assessment questionnaire. Evidence of depression among members of the group came from physician diagnosis, patient reports of having a prescription for an antidepressant in the year before the survey, or patient answers to a brief screening test. For the next two years, the research team recorded the death and cause of death of participants through bi-monthly checks of Medicare claims and eligibility files, or from phone calls with the participants' families.
READ MORE @ EUREKALERT
In a large group of Medicare beneficiaries with diabetes, depression was associated with a higher death rate from all causes during a two-year study period. The findings are published in the October 2008 Journal of General Internal Medicine.
Lead author Dr. Wayne Katon, professor of psychiatry and behavioral sciences at the University of Washington (UW), noted that previous research indicates that depression and diabetes is a potentially lethal mix among young to middle-aged patients. Depression also puts patients at greater risk of complications from their diabetes. This more recent study suggests that depression is also a risk factor for mortality in older patients with diabetes. Most Medicare beneficiaries, like the ones in this study, are over age 65. The mean age of the participants was 75.6 years.
The study tracked 10,704 Medicare beneficiaries with diabetes who were enrolled in a disease management program in Florida. They were surveyed at the start of the study with a health assessment questionnaire. Evidence of depression among members of the group came from physician diagnosis, patient reports of having a prescription for an antidepressant in the year before the survey, or patient answers to a brief screening test. For the next two years, the research team recorded the death and cause of death of participants through bi-monthly checks of Medicare claims and eligibility files, or from phone calls with the participants' families.
READ MORE @ EUREKALERT
Wednesday, October 1, 2008
AHRQ Study: Conventional Antipsychotics May Pose Risk To Elderly
Elderly patients who are prescribed a conventional, or first-generation, antipsychotic medication are at an increased risk of death from cardiovascular or respiratory diseases, as compared to those who take an atypical, or second-generation, antipsychotic medication, according to a study funded by the Agency for Healthcare Research and Quality.
The new study, "Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic Medications," which was recently posted online in the Journal of the American Geriatrics Society, adds to growing evidence that conventional antipsychotics may not be safer than atypical anitpsychotics for the elderly. Researchers had previously identified that such second-generation medications may pose increased mortality. The new study compares specific causes of death among elderly patients newly started on conventional versus atypical antipsychotics.
READ MORE @ U.S. MEDICINE
The new study, "Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic Medications," which was recently posted online in the Journal of the American Geriatrics Society, adds to growing evidence that conventional antipsychotics may not be safer than atypical anitpsychotics for the elderly. Researchers had previously identified that such second-generation medications may pose increased mortality. The new study compares specific causes of death among elderly patients newly started on conventional versus atypical antipsychotics.
READ MORE @ U.S. MEDICINE
Tuesday, September 30, 2008
Persons With Serious Mental Illness Face Higher Prevalence of Obesity
Obesity is a public health crisis within the general population; however, overweight and obesity issues are even more prevalent in persons with serious mental illness, according to a new report, scheduled to be released on October 3, 2008 by the National Association of State Mental Health Program Directors (NASMHPD).
Findings and recommendations from the report appear in the September 22 issue of Mental Health Weekly, making the journal the first major media outlet to inform the public of this new technical report.
NASMHPD calls the crisis "an epidemic within an epidemic," and say they hope the new report will go a long way toward improving the systems that provide care and treatment to the SMI population.
READ MORE @ MARKET WATCH
Findings and recommendations from the report appear in the September 22 issue of Mental Health Weekly, making the journal the first major media outlet to inform the public of this new technical report.
NASMHPD calls the crisis "an epidemic within an epidemic," and say they hope the new report will go a long way toward improving the systems that provide care and treatment to the SMI population.
READ MORE @ MARKET WATCH
Monday, September 29, 2008
U.S. Kids Take More Psychotropic Drugs Than Europeans
American children are three times more likely to be prescribed psychotropic medications for conditions such as ADHD and bipolar disease than European children are, a new study finds.
Differences in regulatory practices and cultural beliefs about the benefit of medication for emotional and behavioral problems may explain this dramatic difference, the U.S. researchers added.
"There is significantly greater use of atypical antipsychotics and SSRI-type antidepressants for child mental health treatment in U.S. than in Western Europe," said lead researcher Julie Zito, from the pharmaceutical health services research department in the School of Pharmacy at the University of Maryland. "Since most of the use is 'off-label' -- without adequate evidence of benefits and risks, close monitoring should be considered when these medications are used."
The report was published in the Sept. 24 online edition of Child and Adolescent Psychiatry and Mental Health.
READ MORE @ FORBES
Differences in regulatory practices and cultural beliefs about the benefit of medication for emotional and behavioral problems may explain this dramatic difference, the U.S. researchers added.
"There is significantly greater use of atypical antipsychotics and SSRI-type antidepressants for child mental health treatment in U.S. than in Western Europe," said lead researcher Julie Zito, from the pharmaceutical health services research department in the School of Pharmacy at the University of Maryland. "Since most of the use is 'off-label' -- without adequate evidence of benefits and risks, close monitoring should be considered when these medications are used."
The report was published in the Sept. 24 online edition of Child and Adolescent Psychiatry and Mental Health.
READ MORE @ FORBES
Sunday, September 28, 2008
Antidepressants 'may harm sperm'
Drugs taken by millions of men to alleviate depression may affect their fertility, say US scientists.
A small number of healthy men given the antidepressant paroxetine for four weeks had far higher levels of sperm with damaged DNA.
The results, reported in New Scientist magazine, do not necessarily mean these men would have serious problems becoming a father.
However, a UK fertility specialist said they were a "cause for concern".
Paroxetine, sold as Seroxat or Paxil, is one of the most commonly prescribed antidepressants in the UK.
This is the second study by a team of researchers at Cornell Medical Center in New York which points to a possible effect on sperm quality.
READ MORE @ BBC
A small number of healthy men given the antidepressant paroxetine for four weeks had far higher levels of sperm with damaged DNA.
The results, reported in New Scientist magazine, do not necessarily mean these men would have serious problems becoming a father.
However, a UK fertility specialist said they were a "cause for concern".
Paroxetine, sold as Seroxat or Paxil, is one of the most commonly prescribed antidepressants in the UK.
This is the second study by a team of researchers at Cornell Medical Center in New York which points to a possible effect on sperm quality.
READ MORE @ BBC
Friday, September 26, 2008
Understanding preemption, Part II
This is Part 2 of a letter to the editor that discusses preemption in the health industry, citing Dr. Bruce West in a Health Alert newsletter from August of this year.
To the Editor:
"The list of drugs known in advance to be dangerous with sometimes lethal side effects, is long indeed. There have been a dozen just in the last few years - always with the drugmakers' attempts to obscure, cover up, mask, lie, and hide the truth before it is finally revealed to the public in a court case. It is all routine.
READ MORE @ MARSHALL INDEPENDENT
To the Editor:
"The list of drugs known in advance to be dangerous with sometimes lethal side effects, is long indeed. There have been a dozen just in the last few years - always with the drugmakers' attempts to obscure, cover up, mask, lie, and hide the truth before it is finally revealed to the public in a court case. It is all routine.
READ MORE @ MARSHALL INDEPENDENT
Thursday, September 25, 2008
Understanding preemption
To the Editor:
If a company created a product which caused injury and/or death, would you be outraged and demand corrective action, i.e. lawsuit, etc.?
I would, and I believe you would also. Do the tobacco companies come to mind? Of course, many states redirected funds into areas foreign to their original agreement with the court, but who cares, they are the government. Right?
Well, when it comes to your health, loosen up, because the drug industry wants to be exempt from damage awards due to injuries or death caused by their drugs, medical devices, etc. It is referred to in law circles as preemption!
To come to a more comprehensive understanding of what this entails, I refer you to what Dr. Bruce West said in his Health Alert newsletter, dated August 2008, Volume 25, Issue 8, pp. 1-2. This will be a two part letter, due to length.
READ MORE @ MARSHALL INDEPENDENT
If a company created a product which caused injury and/or death, would you be outraged and demand corrective action, i.e. lawsuit, etc.?
I would, and I believe you would also. Do the tobacco companies come to mind? Of course, many states redirected funds into areas foreign to their original agreement with the court, but who cares, they are the government. Right?
Well, when it comes to your health, loosen up, because the drug industry wants to be exempt from damage awards due to injuries or death caused by their drugs, medical devices, etc. It is referred to in law circles as preemption!
To come to a more comprehensive understanding of what this entails, I refer you to what Dr. Bruce West said in his Health Alert newsletter, dated August 2008, Volume 25, Issue 8, pp. 1-2. This will be a two part letter, due to length.
READ MORE @ MARSHALL INDEPENDENT
Wednesday, September 24, 2008
Statins Increase Risk Of Postoperative Delirium In Elderly Patients, Study Suggests
The use of statins is associated with a 28% increased risk of postoperative delirium in elderly patients, found University of Toronto professor Dr. Donald Redelmeier and colleagues in a retrospective cohort analysis involving more than 280 000 patients.
Ontario's Institute for Clinical Evaluative Sciences (ICES) looked at elderly patients who underwent elective surgery in Ontario and who had received 2 or more prescriptions for statins in the year before surgery, including at least one prescription in the 90 days preceding surgery. Many patients took multiple medications, underwent abdominal, musculoskeletal or urogenital surgery which had a mean duration of about 115 minutes.
Delirium, in addition to causing anxiety in patients and families, contributes to longer hospital stays, a prolonged need for intensive care, and can disrupt and delay care.
READ MORE @ SCIENCE DAILY
Ontario's Institute for Clinical Evaluative Sciences (ICES) looked at elderly patients who underwent elective surgery in Ontario and who had received 2 or more prescriptions for statins in the year before surgery, including at least one prescription in the 90 days preceding surgery. Many patients took multiple medications, underwent abdominal, musculoskeletal or urogenital surgery which had a mean duration of about 115 minutes.
Delirium, in addition to causing anxiety in patients and families, contributes to longer hospital stays, a prolonged need for intensive care, and can disrupt and delay care.
READ MORE @ SCIENCE DAILY
Tuesday, September 23, 2008
Inside Medicine: Doctors torn by end-of-life philosophies
Doctors and the American public are afraid to let people die – and even help them do so – with comfort and dignity.
That has become clear to me over my 20 years of practice and through the stories that my colleagues have shared with me.
One doctor e-mailed me about his patient, a woman of 80, who found herself dying of emphysema. Despite being tethered to green oxygen cylinders and having her face constantly enmeshed in clear plastic face masks, she was continually short of breath.
Talking was very difficult and walking even short distances was out of the question. Faced with a terminal illness, she chose hospice care rather than spend her last days in a hospital.
She asked for a pill to end her life. The doctor told her she was depressed (which, given her situation, she might well have been). He offered antidepressant medications. She refused – "no more treatments."
READ MORE @ SACRAMENTO BEE
That has become clear to me over my 20 years of practice and through the stories that my colleagues have shared with me.
One doctor e-mailed me about his patient, a woman of 80, who found herself dying of emphysema. Despite being tethered to green oxygen cylinders and having her face constantly enmeshed in clear plastic face masks, she was continually short of breath.
Talking was very difficult and walking even short distances was out of the question. Faced with a terminal illness, she chose hospice care rather than spend her last days in a hospital.
She asked for a pill to end her life. The doctor told her she was depressed (which, given her situation, she might well have been). He offered antidepressant medications. She refused – "no more treatments."
READ MORE @ SACRAMENTO BEE
Monday, September 22, 2008
No longer depressed, or on meds
Doctors show new interest in mind-body therapies for mental illness and are using everything from herbs to meditation and massage to treat depression without medication.
Henry Quant was just 5 years old and bedridden with chronic fevers when he began taking pills for anxiety and depression.
His mother knew that the drugs helped, but they made her nervous.
"The really scary part," Elizabeth Quant said, "is we don't know what these do long term."
This summer, under the watchful eye of his physician, Henry, now 7, replaced his antidepressants with vitamins and learned some stress-relief exercises to calm himself.
READ MORE @ MINNEAPOLIS STAR TRIBUNE
Henry Quant was just 5 years old and bedridden with chronic fevers when he began taking pills for anxiety and depression.
His mother knew that the drugs helped, but they made her nervous.
"The really scary part," Elizabeth Quant said, "is we don't know what these do long term."
This summer, under the watchful eye of his physician, Henry, now 7, replaced his antidepressants with vitamins and learned some stress-relief exercises to calm himself.
READ MORE @ MINNEAPOLIS STAR TRIBUNE
Sunday, September 21, 2008
The Tyranny of Diagnosis
Not long ago, while surfing online for one disease, I got sidetracked by another: cryptogenic cirrhosis.
I have cared for patients with cryptogenic cirrhosis. It is a common cause of liver-related illness and death in the United States, and symptoms can range from jaundice, bleeding and confusion to life-threatening hemorrhage, coma and death.
The cause of the disease, as the name implies (from the Greek “krypt,” or hidden, and “genesis,” or origin), has long been unknown. Every one of my patients with cryptogenic cirrhosis has heard the same thing from their doctors, including myself: “We have no idea why you are so sick.”
For these patients, cryptogenic cirrhosis is not a diagnosis but a non-diagnosis.
READ MORE @ NY TIMES
I have cared for patients with cryptogenic cirrhosis. It is a common cause of liver-related illness and death in the United States, and symptoms can range from jaundice, bleeding and confusion to life-threatening hemorrhage, coma and death.
The cause of the disease, as the name implies (from the Greek “krypt,” or hidden, and “genesis,” or origin), has long been unknown. Every one of my patients with cryptogenic cirrhosis has heard the same thing from their doctors, including myself: “We have no idea why you are so sick.”
For these patients, cryptogenic cirrhosis is not a diagnosis but a non-diagnosis.
READ MORE @ NY TIMES
Saturday, September 20, 2008
Medical Panel Disproves Psychiatric Theory - Finding No Evidence of Schizophrenia as Genetic Disease
After 25 years of psychiatric research attempting to single out a genetic component to verify the medical existence of schizophrenia, a panel of medical researchers from Australia, France and the United States concluded that no such genes exist, nullifying the genetic theory that psychiatrists have passed off as factual despite any conclusive evidence.
The study entitled “No Significant Association of 14 Candidate Genes with Schizophrenia in a Large European Ancestry Sample: Implications for Psychiatric Genetics,” published in the American Journal of Psychiatry found there is no significant association of schizophrenia with hereditary markers previously thought to be indicative of it.
“Research has never shown any link between genes and schizophrenia,” said Mary Boyle, emeritus professor of clinical psychology from the University of East London. “There has been a vast amount of time and money spent. Yet nothing has come from it. If people want to continue this research, good luck to them. But my worry is that they are being given public funding.”
READ MORE @ PR URGENT
The study entitled “No Significant Association of 14 Candidate Genes with Schizophrenia in a Large European Ancestry Sample: Implications for Psychiatric Genetics,” published in the American Journal of Psychiatry found there is no significant association of schizophrenia with hereditary markers previously thought to be indicative of it.
“Research has never shown any link between genes and schizophrenia,” said Mary Boyle, emeritus professor of clinical psychology from the University of East London. “There has been a vast amount of time and money spent. Yet nothing has come from it. If people want to continue this research, good luck to them. But my worry is that they are being given public funding.”
READ MORE @ PR URGENT
Subscribe to:
Posts (Atom)
